Gilead Sciences Inc.’s stock rose 2% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19 treatments.
Source: MarketWatch
Thursday, 07. November 2024
Share:
06. November 2024 22:36
Gilead’s third-quarter earnings beat by a wide margin, and biotech raises guidance
